The role of salvage treatment in advanced colorectal cancer

Critical Reviews in Oncology/Hematology

Volumn 71, Issue 1, 2009, Pages 53-61

  Capdevila, Jaume ^a   Ramos, Francisco Javier ^a   Macarulla, Teresa ^a   Elez, Elena ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bevacizumab; Cetuximab; Chemotherapy; Colorectal cancer; Salvage therapy; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB; PEMETREXED; RALTITREXED; UFT;

ACNE; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LIVER METASTASIS; LIVER RESECTION; OVERALL SURVIVAL; RASH; REVIEW; SALVAGE THERAPY;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; SALVAGE THERAPY;

EID: 67349175311     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.09.006     Document Type: Review

References (66)

1. Grothey A., Sargent D., Goldberg R.M., and Schmoll H.-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 7 (2004) 1209-1214
2. Rothenberg M.L. Current status of second-line therapy for metastatic colorectal cancer. Clin Colorectal Cancer 4 1 (2004) 16-21
3. Cunningham D., Pyrhönen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 9138 (1998) 1413-1418
4. Rougier P., Van Cutsem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 9138 (1998) 1407-1412
5. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 9582 (2007) 135-142
6. Seymour M.T., Maughan T.S., Ledermann J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 9582 (2007) 143-152
7. Rougier P., Lepille D., Bennouna J., et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 13 10 (2002) 1558-1567
8. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21 11 (2003) 2059-2069
9. Pfeiffer P., Glimelius B., Sørbye H., et al. Phase II study of short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) in patients with progressive colorectal cancer after irinotecan and 5-fluorouracil (FU) treatment. Proc Am Soc Clin Oncol 22 14S (2004) 3562
10. Maindrault-Goebel F., Louvet C., André T., et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35 9 (1999) 1338-1342
11. Rothenberg M., Navarro M., Butts C.A., et al. Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): phase II trial results. Eur J Cancer 5 4 (2007) A3012
12. Giantonio B.J., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 23 16S (2005) 2
13. Haller DG, Rothenberg ML, Wong AO, et al. Final results of a randomized phase III trial comparing irinotecan + oxaliplatin (IROX) to irinotecan monotherapy in patients with metastatic colorectal cancer (MCRC) previously treated with fluoropyrimidines. Ann Oncol 2004;15(Suppl. 3)(70):abstr 263 O.
14. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 2 (2004) 229-237
15. Pitot H.C., Rowland K.M., Sargent D.J., et al. N9841: a randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU. Proc Am Soc Clin Oncol 23 16S (2005) 3506
16. Rowland K.M., Pitot H.C., Sargent D.J., et al. Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy. Proc Am Soc Clin Oncol 23 16S (2005) 3519
17. Gholam D., Giacchetti S., Brezault Bonnet C., et al. Chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L), and oxaliplatin (O) (chrono IFLO) as salvage therapy in oxaliplatin- and irinotecan-resistant advanced colorectal cancer (ACRC): treatment results and toxicity profile. Proc Am Soc Clin Oncol 22 14S (2004) 3551
18. Bouchahda M., Adam R., Giacchetti S., et al. Effective salvage therapy of liver-only colorectal cancer metastases with chronomodulated irinotecan-fluorouracil-oxaliplatin via hepatic artery infusion. Proc Am Soc Clin Oncol 24 18S (2006) 3585
19. Ziras N., Potamianou A., Varthalitis I., et al. Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Oncology 70 2 (2006) 106-114
20. Lonardi S., Paris M.K., Stefani M., et al. Gemcitabine (GEM) as salvage therapy in patients (pts) with advanced colorectal cancer (CRC) refractory to 5-fluorouracil (FU), irinotecan (IRI) and oxaliplatin (OXA). Proc Am Soc Clin Oncol 22 14S (2004) 3577
21. Rodriguez J., Viudez A., Salgado E., et al. Irinotecan and mitomycin C (MMC) as salvage therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, irinotecan and/or oxaliplatin based chemotherapy. Proc Am Soc Clin Oncol 22 14S (2004) 3758
22. Gennatas C.G., Michalaki V., Gennatas S., Kouvaris J., Smyrniotis V., and Vasiliou J. Mitomycin-C and capecitabine as salvage chemotherapy in pre-treated patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 25 18S (2007) 14595
23. Lim D.H., Park Y.S., Park B.B., et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 56 1 (2005) 10-14
24. Rosati G., Rossi A., Germano D., Reggiardo G., and Manzione L. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res 23 3C (2003) 2981-2985
25. Vormittag L., Kornek G.V., Gruhsmann B., et al. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer-a retrospective analysis. Anticancer Drugs 18 6 (2007) 709-712
26. Louvet C., Andre T., Gamelin E., et al. Antitumour activity of pemetrexed (Pem) and irinotecan (Iri) in second-line metastatic colorectal cancer (MCRC) patients: a multicenter phase II study. Proc Am Soc Clin Oncol 25 18S (2007) 4103
27. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21 14 (2003) 2787-2799
28. Mayer A., Takimoto M., Fritz E., Schellander G., Kofler K., and Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71 8 (1993) 2454-2460
29. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 7 (2004) 1201-1208
30. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
31. Wilke H., Glynne-Jones R., Thaler J., et al. MABEL-A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. Proc Am Soc Clin Oncol 24 18S (2006) 3549
32. Lenz H.-J., Van Cutsem E., Khambata-Ford S., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24 30 (2006) 4914-4921
33. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 20 (2007) 2040-2048
34. Scheithauer W., Sobrero A.F., Lenz H., et al. Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial. Eur J Cancer 5 4 (2007) 3003
35. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 13 (2007) 1658-1664
36. Lievre A., Bachet J.-B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 8 (2006) 3992-3995
37. Lievre A., Bachet J.-B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26 3 (2008) 374-379
38. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67 6 (2007) 2643-2648
39. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96 8 (2007) 1166-1169
40. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19 3 (2008) 508-515
41. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25 22 (2007) 3230-3237
42. Finocchiaro G., Cappuzzo F., Jänne P.A., et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. Proc Am Soc Clin Oncol 25 18S (2007) 4021
43. Amado R.G., Wolf M., Freeman D., et al. Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. ASCO Gastrointest Cancers Symp (2008) 278
44. Chen H.X., Mooney M., Boron M., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an nci treatment referral center trial TRC-0301. J Clin Oncol 24 21 (2006) 3354-3360
45. Ciardiello F., Bianco R., Damiano V., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6 9 (2000) 3739-3747
46. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5 3 (2007) 203-220
47. Saltz L.B., Lenz H.-J., Kindler H.L., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25 29 (2007) 4557-4561
48. Hecht J.R., Mitchell E., Chidiac T., et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). ASCO Gastrointest Cancers Symp (2008) 273
49. Punt C.J., Tol J., Rodenburg C.J., et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). Proc Am Soc Clin Oncol 26 (2008) LBA4011
50. Kuo T., Cho C.D., Halsey J., et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 23 24 (2005) 5613-5619
51. Rothenberg M.L., LaFleur B., Levy D.E., et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 23 36 (2005) 9265-9274
52. Kindler H.L., Friberg G., Skoog L., Wade-Oliver K., and Vokes E.E. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol 28 4 (2005) 340-344
53. Mackenzie M.J., Hirte H.W., Glenwood G., et al. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 23 2 (2005) 165-170
54. Townsley C.A., Major P., Siu L.L., et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94 8 (2006) 1136-1143
55. Keilholz U., Arnold D., Niederle N., et al. Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial. Proc Am Soc Clin Oncol 23 16S (2005) 3575
56. Hanauske A.R., Diaz-Rubio E., Cassidy J., et al. Erlotinib HCL in combination with FOLFOX4 in patients with solid tumors. Proc Am Soc Clin Oncol 22 (2003) 789
57. Meyerhardt J.A., Zhu A.X., Enzinger P.C., et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 24 12 (2006) 1892-1897
58. Delord J.P., Beale P., Van Cutsem E., et al. A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients. Proc Am Soc Clin Oncol 22 14S (2004) 3585
59. Allen P.J., Kemeny N., Jarnagin W., DeMatteo R., Blumgart L., and Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7 1 (2003) 109-115
60. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 6 (2004) 1052-1061
61. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240 4 (2004) 644-657
62. Adam R., Aloia T., Levi F., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25 29 (2007) 4593-4602
63. Mocellin S., Pilati P., Lise M., and Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. J Clin Oncol 25 35 (2007) 5649-5654
64. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23 22 (2005) 4888-4896
65. Ducreux M., Ychou M., Laplanche A., et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: A trial of the Gastrointestinal Group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23 22 (2005) 4881-4887
66. Gallagher D.J., Capanu M., Raggio G., and Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 18 12 (2007) 1995-1999